Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase (HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (Po0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesininduced p300 HAT activity, we examined Src and PKCd pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCd inhibitors or PKCd siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCd kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesininduced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCd signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.
Introduction
The majority of androgen-independent (ablation-resistant) prostate cancers (PC) continue to express androgen receptor (AR) following androgen withdrawal (Bubendorf et al., 1999; Sadar et al., 1999) . Several lines of evidence indicate that AR is activated both in ligand-dependent and ligand-independent manners (Lee et al., 2001; Dai et al., 2002) . AR-mediated gene transcription is significantly increased in DU145 cells transiently expressing AR by epidermal growth factor (EGF), insulin-like growth factor I (IGF-I), and keratinocyte growth factor (KGF) (Culig et al., 1994) . Interleukin-6 (IL-6)-mediated activation of AR was also reported in LNCaP cells (Debes et al., 2002) . Overexpression of the HER-2/neu receptor tyrosine kinase by PC cells also results in ligand-independent activation of AR signaling and prostate-specific antigen (PSA) production (Culig et al., 2000 (Culig et al., , 2002 . In addition to growth factors and ligands, several AR coactivators have shown to enhance AR activities, including the p160 proteins, the p300/CREB-binding protein (CBP) family, Ubc9, ARA70, ARA55, and TIP60 (McKenna et al., 1999; Heinlein and Chang, 2002; Kang et al., 2004) .
P300 is an important and versatile coactivator common to many steroid receptors (Giordano and Avantaggiati, 1999) . P300 was originally identified as a protein that bound to the adenoviral E1A and cAMPresponse element-binding protein (CREB) (for a review see Fu et al., 2002a) . P300 conveys a bridging function between DNA-bound transcription factors and the basal apparatus, providing a scaffold to assemble highmolecular-weight enhanceosomes (Vo and Goodman, 2001 ). In addition, p300 is endowed with histone acetyltransferase (HAT) activity that transfers an acetyl group to the e-amino group of a lysine residue to acetylate histones and nonhistone proteins including nuclear receptors (Fu et al., 2000 (Fu et al., , 2004a Chan and La Thangue, 2001 ). The coactivator p300 augments AR activity, in part, related to its intrinsic HAT activity (Fu et al., 2000 (Fu et al., , 2003 . The AR is directly acetylated by p300, P/CAF and TIF60 at a phylogenetic conserved motif within the hinge region (Fu et al., 2000) . Gain of function mutants of the AR enhances AR activity and promote prostate cellular growth suggesting a key role for AR acetylation in prostate cellular growth control (Fu et al., 2002b (Fu et al., , 2004a .
Recent evidence indicates that the expressions of p300/CBP genes are altered in various human tumors (Gayther et al., 2000; Chim et al., 2004; Shigeno et al., 2004 ). The higher than normal level of p300 in PC biopsies predicts for larger tumor volumes, extraprostatic extension as well as PC progression after surgery. There is also a trend towards a positive correlation between p300 expression and higher Gleason scores in PC (Debes et al., 2003) .
Numerous studies support a link between neuroendocrine differentiation, tumor progression, and the development of androgen-independent PC (Bologna et al., 1989; Aprikian et al., 1997 Aprikian et al., , 1998 ; for a review see Vashchenko and Abrahamsson, 2005) . We have studied the involvement of the neuropeptide bombesin in PC progression and shown that (1) bombesin induces FAK phosphorylation in PC cells in a Src-dependent manner resulting in PC cell migration; (2) bombesin induces ligand-independent phosphorylation of the IGF-1 receptor and Akt in PC cells, promoting cell survival; (3) neuropeptides mediates cSrc kinase activation, which induces rapid PKCd degradation and TPAresistance in PC Cells (Sumitomo et al., 2000a (Sumitomo et al., , b, 2001 ; and (4) bombesin can synergize with low (castrate) levels of dihydrotestosterone (DHT) to induce AR-mediated transcription (Dai et al., 2002) . In addition, Borre et al. (2000) reported that bombesin stimulation of GRP receptors results in increased expression of the proangiogenic factors interlukin-8 (IL-8) and vascular endothelial growth factor (VEGF) through an NFkB-dependent pathway (Borre et al., 2000; Levine et al., 2003) . Together, these studies suggest that bombesin contributes to PC progress.
The mechanisms by which bombesin augments AR signaling is unknown. In the current study, we investigated the interaction of bombesin and p300. We report that bombesin regulates the HAT activity of the AR coactivator p300. Bombesin-induced p300 HAT activity, mediated via Src and PKCd signaling, consequently results in AR acetylation and AR transactivation, leading to the increased expression of ARregulated genes in PC cells.
Results
Bombesin induces p300 HAT activity P300 possesses HAT activity (Chan and La Thangue, 2001; Fu et al., 2004a, b) . The acetylation level of chromatin and nonhistone proteins is a key mechanism in regulating transcription. P300 stimulates AR acetylation in the presence of 100 nM DHT (Fu et al., 2003) . To elucidate the role of p300 in the AR pathway in the presence of bombesin, we analysed p300 HAT activities in the presence of 50 nM bombesin in medium containing 5% charcoal stripped (CS) sera in PC-3 cells (Figure 1a , upper panel) and C4-2 cells (Figure 1b, upper panel) . The reason for using medium containing CS instead of fetal bovine serum (FCS) in our experiments was to examine the effect of bombesin under low androgen levels similar to the physiological condition following castration. At 4 h after the addition of bombesin, p300 HAT activities reached their maximum values (B2.0-fold relative to 0 h, Po0.01). Immunoprecipitation (IP) Western assays demonstrated equal amounts of p300 proteins were precipitated by anti-p300 antibody for HAT assays (Figure 1a and b, lower panel). We next analysed p300 HAT activities in the presence of various concentrations of bombesin. As shown in Figure 1c and d, at concentrations of 50 and 100 nM bombesin, the p300 HAT activities increased 2.2-and 2.5-fold in PC-3 cells (Po0.01, Figure 1c) , or 2.0-and 2.2-fold in C4-2 cells (Po0.01, Figure 1d ). The linear increase of HAT activities by increased concentrations of bombesin indicated that bombesin-induced p300 HAT activity was dose dependent.
We next measured the HAT activities of p300 in the presence of neutral endopeptidase (NEP), which degrades bombesin, or bombesin receptor antagonists (Papandreou et al., 1998) . As shown in Figure 1e (PC-3 cells) and Figure 1f (C4-2 cells), treatment with NEP or bombesin receptor antagonists reversed bombesininduced p300 HAT activities. These data indicate that bombesin induces p300 HAT activities in PC cells.
PKCd signaling interferes with bombesin-induced p300 HAT activities P300 is a nuclear phosphoprotein subject to regulate by phosphorylation in response to a number of specific cellular-signaling pathways (Yaciuk and Moran, 1991) . We previously reported that bombesin activation of Src kinase results in PKCd degradation (Sumitomo et al., 2000b) . PKCd was recently shown to specifically phosphorylate p300 at Serine 89 in vivo and in vitro, leading to inhibition of p300 intrinsic HAT activity (Yuan and Gambee, 2000; Yuan et al., 2002) . Therefore, we tested the effects of inhibitors (or activators) of Src and PKCd kinases on bombesin-mediated p300 HAT activity. Bombesin-induced p300 HAT activities were abrogated by the Src kinase inhibitor PP2 in PC-3 The KLKK motif of AR protein is both necessary and sufficient for acetylation by p300 in the presence of 100 nM DHT (Fu et al., 2000) . To further identify the acetylation sites of AR in the presence of bombesin, we employed the AR mutant AR-A in which the Lysine 630 (in the KLKK motif) was mutated into alanine to . These data suggest that bombesin-induced AR acetylation occurs at the KLKK motif similar to that observed using 100 nM DHT.
PKCd signaling is responsive for AR acetylation in presence of bombesin The above results demonstrate that bombesin induces p300 HAT activity. The induction was GPCR specific and mediated by PKCd signaling. We also showed that augmented p300 HAT activities resulted in enhanced AR acetylation. These observations imply a direct link between AR acetylation and PKCd signaling, which mediates bombesin-induced p300 activity. To confirm this, we examined the acetylation of AR in the presence of NEP, bombesin receptor antagonists, and inhibitors or activators of PKCd signaling. As shown in Figure 5 , bombesin-induced AR acetylation (lane 2) was eliminated in the presence of NEP (lane 3) or the bombesin antagonist H3026 (lane 4). Increased acetylation of AR (lane 5) and reduced acetylation (lane 6) resulted from incubation with a PKCd inhibitor and PKC activator, respectively. These data indicate that bombesin-induced AR acetylation is also bombesin receptor specific and mediated by PKCd signaling. Next, to assess whether bombesin-induced AR acetylation is directly mediated by p300, we transfected p300 siRNA together with an AR expression vector into PC-3 cells and measured AR acetylation using an acetylation specific antibody. AR was detected in cells transfected with an AR expression vector ( Figure 6a , panel 2; lanes 1-6), but not control cells ( Figure 6a , panel 2; lanes 7 and 8). When blotted with an acetylation-specific antibody, the presence of p300 siRNA reduced bombesin-induced AR acetylation (Figure 6a , comparing lanes 5 and 6 with lanes 1 and 2 in panel 1). Bombesin-induced AR acetylation was not detected in lanes 3 and 4 ( Figure 6a , panel 1), likely due to the higher expression of exogenous p300 overriding the effect of bombesin. Western analysis showed the reduced expression of endogenous p300 protein by p300 siRNA in PC-3 cells (Figure 6a , lanes 5 and 6 of panel 3). To assess the effect of endogenous p300 on Figure 3 Bombesin-induced p300 HAT can be blocked by eliminating endogenous Src kinase and PKCd with siRNAs specific to cSrc and PKCd. (a and b): PC-3 (a) and C4-2 (b) cells were transfected without (Con) or with nontargeting siRNA (siRNA Con), cSrc siRNA (siRNA cSrc). After 48 h, cells were treated without (ÀBBS, dark bars) or with 50 nM bombesin ( þ BBS, gray bars) for 4 h. Samples were collected and HAT activities were measured as described before. (c and d) PC-3 (c) and C4-2 (d) were subjected to the similar treatments with PKCd siRNA instead of cSrc siRNA and measurements of HAT activities were performed as described before.
Activation of p300 HAT activity and acetylation of the AR by bombesin in PC cells J Gong et al bombesin-induced AR acetylation, we next examined AR acetylation by suppressing p300 expression with p300 siRNA in C4-2 cells. As shown in Figure 6b , overexpression of p300 led to augmented acetylation of AR (lane 3 of Figure 6b ), whereas suppression of endogenous p300 by p300 siRNA reduced AR acetylation (lane 4, Figure 6b ) compared to control (lanes 1 and 2, Figure 6b ). Together, these data indicate that reduced p300 expression by siRNA suppresses bombesininduced AR acetylation, suggesting that bombesininduced acetylation of AR is mediated by p300.
Bombesin-induced acetylation transactivates AR and promotes the expression of PSA To assess the functional significance of bombesininduced AR acetylation, we transfected wt-AR(or mutant) together with pProbasin(ARR) 3 tkluc (containing three copies of the androgen responsive regions of the Probasin gene linked to thymidine kinase minimal promoter and luciferase reporter gene) into PC-3 cells. Bombesin increased luciferase activities in the presence of wt-AR (B10-fold) (Figure 7a, lane 3) . Transfection of the AR-A mutant led to a reduction in luciferase activities, indicating that AR acetylation is required for bombesin-induced AR activity (Figure 7a, lane 4) . To further examine the role of p300 in bombesin-induced AR activity, we transfected the p300 expression vector alone and together with p300 siRNA and measured luciferase activities. As shown in Figure 7b , overexpression of p300 enhanced luciferase activities (B2 folds) (Figure 7b, lanes 2 and 4) . However, when cotransfected with p300 siRNA, bombesin-induced luciferase activities were reduced to 37% relative to that without p300 siRNA (comparing lane 5 with lane 2 -6) , p300 (lanes 3 and 4) and siRNA of p300 (sip300) (lanes 5 and 6) individually or in combination. After 24 h, treatments were performed in presence (lanes 2, 4, 6 and 8) or absence (lanes 1, 3, 5 and 7) of 50 nM bombesin (BBS). Two top panels are IP Western analysis by anti-AR antibody and then blotted with antiacetylated lysine (Ac-lysine), anti-AR (anti-AR) antibodies. Two bottom panels are Western analysis of these cell lysates with anti-p300 (anti-p300) and anti-b-Actin (anti-actin) antibodies. Vector (lanes 7 and 8) means empty vector used as negative control. (b) C4-2 cells were transfected with nontargeting siRNA (lanes 1 and 2), p300 expression vector (lane 3) and p300 siRNA (lane 4). After 48 h, cells were treated without (lane 1) or with 50 nM bombesin (BBS þ , lanes 2-4) for 4 h. Cell lysates were immunoprecipitatted with an AR antibody and blotted with antiacetylation and anti-AR antibodies as described above.
Activation of p300 HAT activity and acetylation of the AR by bombesin in PC cells
J Gong et al in Figure 7b ). In contrast, no effects were observed in control cells (mock transfection) or cells transfected with nontargeting siRNA (lanes 1 and 6 in Figure 7b ). It had previously been reported that CBP also possesses HAT activity (Chan and La Thangue, 2001 ). To determine whether the luciferase activities which remained (37%) following suppression of p300 by p300 siRNA were mediated by CBP, we assessed the effect on bombesininduced luciferase activities of overexpressing CBP in PC-3 cells. Overexpression of CBP had no effect on bombesin-induced luciferase activities, suggesting that bombesin-induced AR acetylation was not mediated by CBP (Figure 7b ). Finally, to confirm the involvement of the above signaling pathways and p300 on bombesin's function in vivo, we measured the expression of the AR-regulated gene PSA. We assessed the effects of inhibitors and activators of Src kinase and PKCd pathways on PSA expression. As shown in Figure 7c , PP2 and PMA (lanes 4 and 8) reduced, but the PKC inhibitor (PKI) Plasmids, pProbasinARRtkluc and wt-AR, were cotransfected without (À) or with ( þ ) empty vector (pcDNA3), CBP expression vector (CBP), p300 expression vector (p300), p300 siRNA (si p300) or nontargeting siRNA (si con) into PC-3 cells. After treated without (ÀBBS, dark bars)) or with 50 nM bombesin ( þ BBS, gray bars). In both (a and b), cell lysates were subjected to analysis of luciferase activities. Results were expressed as the relative percentage of luciferase activity, with the values resulting from no treatment set to 100%. Mean values were calculated from three independent experiments performed in duplicate, Po0.001. Bars, s.e. (c) Western analysis showing bombesin-induce expression of PSA was mediated by Src kinase, PKCd signaling. LNCaP cells were treated without (À) (lanes 1, 3, 5 and 7) and with ( þ ) 50 nM bombesin (BBS) (lanes 2, 4, 6 and 8), following pretreatments without (lanes 1 and 2) or with 10 mM PP2 (lanes 3 and 4), 6 mM rotterin (lanes 5 and 6) and 10 nM PMA (lanes 7 and 8). Cell lysates were resolved by 7.5% SDS PAGE and blots were detected with anti-PSA (top panel) and anti-b-actin (bottom panel) antibodies. (d) Bombesin-induced PSA expression is mediated by p300. LNCaP cells were transfected with either control buffer (lanes 1 and 2), nontargeting siRNA (lane 3) or p300 siRNA (lane 4). Cells were subsequently treated without (NC) or with 50 nM bombesin ( þ BBS) (lanes 2-4). Cell lysates were subjected to Western analysis with anti-PSA, anti-p300 and antiactin antibodies, respectively. (e and f) are the results of densitometric analysis of (c and d). Autoradiograms were subjected to densitometric analysis using the gel scanner mode of ImageJ software v 1.33 (National Insititutes of Health, Bethesda, MD, USA) and plotted in relative units of actin-normalized pixel counts using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego,CA, USA). GF109203X (lane 6) enhanced bombesin stimulated expression of PSA, relative to the treatment of bombesin alone (lane 2), suggesting that Src kinase and PKCd signaling pathways are involved in bombesin-induced PSA expression. In contrast, no effects on PSA expression of PP2 and PMA and little effect of Rotterin (Rot) were detected (lanes 1, 3, 5 and 7, in Figure 7c ). Rot had been reported to activate p300 HAT activity (Yuan and Gambee, 2000; Bouras et al., 2005) . Our results were in concordance with previous studies. Nevertheless, bombesin treatment led to a higher PSA expression compared to untreated cells (lane 6 vs lane 5, Figure 7c ). We next assessed the role of p300 on PSA expression by Western blot analysis in PC-3 cells. Bombesin-induced PSA expression (lane 2) was suppressed in the presence of p300 siRNA, but not nontargeting siRNA (lanes 3, 4 of Figure 7d ). These data indicate that bombesin-induced expression of PSA is mediated by Src kinase and PKCd pathways. P300 plays a direct role in regulating the expression of ARregulated genes in the presence of bombesin.
Discussion
Post-translational modifications by acetylation and phosphorylation under several circumstances may be an integrated process. These two post-translational processes may be convergent (Cui et al., 2004; Fu et al., 2004b) . On the basis of accumulating evidences that neuropeptides affect several signaling pathways, such as FAK, IGFR-1, Src, PKC and Akt (Sumitomo et al., 2000a (Sumitomo et al., , b, 2001 , and that p300 HAT activity was regulated by kinase signal pathways such as PKC signaling (Yuan et al., 2002) , we hypothesized that bombesin could also regulate p300 HAT activity. In the current study, we show that (1) p300 is a coactivator of bombesin mediated AR transactivation; (2) p300 HAT activity is induced by bombesin via its GPCR; (3) bombesin regulates p300 HAT activity via Src and PKCd signaling; (4) bombesin induces AR acetylation; and (5) bombesin-induced acetylation results in transactivation of AR activities leading to expression of AR-regulated genes (Figure 8) .
A large number of studies suggest that neuroendocrine differentiation correlates with poor prognosis, tumor progression and is androgen independent in PC (Vashchenko and Abrahamsson, 2005) . To simulate the physiological condition of androgen deprivation, we studied the effects of bombesin on AR transactivation under castrate levels of androgen. We used either low concentration of DHT (10 pM) in serum-free medium, or CS sera-containing medium in our experiments. Charcoal treatment removes 90% of steroids from the serum, resulting in a remaining DHT concentration of approximately 6-10 pM, similar to that used in our previous studies (Dai et al., 2002) . Bombesin-activated AR and the antiandrogen (flutamide) inhibited bombesin stimulated cell growth, suggesting that the low level of DHT in CS is required for transactivation of AR (Lee et al., 2001 ). In the current studies, transactivation of AR by p300 was assayed in medium containing 5% CS. Similar results were also obtained in the presence of bombesin and 10 pM DHT concentration (data not shown). Both conditions are representative of the low DHT condition observed following androgen withdrawal.
Regulation of p300 occurs through post-translational modifications including acetylation, sumolation and phosphorylation (Kitabayashi et al., 1995; Yuan and Gambee, 2000; Bouras et al., 2005) . Phosphorylation at Serine 89 inhibits p300 intrinsic HAT activity, through inducing a conformational change of p300 that hinders it is HAT and transcriptional function (Yuan et al., 2002) . Our previous studies demonstrated that bombesin and endothelin-1, via activating Src kinase, lead to the degradation of PKCd (Sumitomo et al., 2000b) . This suggests that a link, bridged by phosphorylation and dephosphorylation of Serine 89 through PKCd signaling, might exist between the effects of neuropeptides and p300 phosphorylation. The results presented in this study demonstrate that bombesin regulate p300 HAT activities via PKCd signaling, indicating that the presence of such a pathway (Figure 8) . Darne et al. (1998) reported that activation of the PKC pathway induced AR activity in breast cancer cells that express AR. These differences in phorbol ester responsiveness may represent tissue-specific differences between prostate and breast-derived cells, possibly in the expression of coactivators and corepressors.
Recent reports show that there are other phosphorylation and kinase pathways involved in the regulation of p300 activity. Schwartz et al. (2003) identified five other phosphorylation sites on p300 (Serine 1849 , Threonines 1851 , 1854 , 1857 , 2279 inducible by C/EBPb in QT-6 cells. They reported that the ability of C/EBP to trigger p300 phosphorylation is shared by other C/EBP family members as well as by other unrelated transcription factors, and suggested that this mechanism may have general relevance for the function of p300 as a coactivator. Yuan et al. (2002) reported that nonSerine 89 phosphorylation stimulated p300 HAT activity. Therefore, although dephosphorylation of PKCd signaling at Serine 89 plays an important role in regulating p300 HAT activity, the influence of phosphorylation on other identified or unknown sites may also be important and potentially may coordinate with dephophorylation regulation at Serine 89 to affect p300 HAT activity.
Our results show that AR acetylation by bombesin occurs at Lys 630 site in the KLKK motif, the same acetylation site involved in activation by DHT (Fu et al., 2000) . Our results also show that p300, but not CBP, mediated AR acetylation that is in concordance with recent observations. Debes et al. (2005) investigated the role of p300 and its homolog CBP in PC cells treated with IL-6 and found that p300 but not CBP-induced activation of PSA in these cells and that p300 HAT activity was critical for activation. However, several studies have also shown that in addition to p300, the AR can be acetylated in vitro by the HAT enzymatic activity of P/CAF and TIP60 (Fu et al., 2000 (Fu et al., , 2002a Gaughan et al., 2002) . AR acetylation may enhance transcriptional activity by affecting DNA binding as evidenced recently by chromatin IP studies (Fu et al., 2003) or regulate interactions with other proteins including N-CoR, HDAC1 and Smad3 (Fu et al., 2002a (Fu et al., , b, 2003 . The fact that the reduced expression of p300 by siRNA in our study did not completely eliminate AR acetylation in PC-3 cells implies that HAT enzymes other than p300 (or CBP) may also contribute to AR acetylation by neuropeptides.
Our data showing that suppression of p300 expression lead to reduced AR transactivation and the expression of PSA are in concordance with the recent observation that p300 also mediates AR transactivation by IL-6. Acetylation through neutralizing positively charged lysines is predicted to affect conformation and thereby protein-protein or protein-DNA interactions. To assess bombesin-mediated signaling pathways in AR transactivation and PSA regulation, we also examined the effects of the inhibitors and activators of signaling pathways affecting bombesin-induced p300 HAT activities. The data confirmed that Src and PKCd pathways regulate the expression of PSA in the presence of bombesin. Together these studies suggest that bombesin-induced p300-mediated AR acetylation may regulate recruitment of AR to specific endogenous androgen responsive elements of AR-regulated genes in the context of local chromatin. As a result, the expression of AR-regulated genes is promoted.
Our previous studies demonstrated that bombesin transactivates the AR through AR phosphorylation (Dai et al., 2002) . Here, we presented another potential pathway through which neuropeptides sensitize and maintain the active AR pathway under androgen withdrawal condition, that is, by activating HAT activity of p300 and acetylating the AR. Several lines of evidence supported our notion: (1) AR acetylation site mimics showed enhanced responsiveness at lower DHT concentrations than wt-AR; (2) ligand-independent AR could be transactivated by p300 in PC cell lines; and (3) AR acetylation mimic mutants conveyed a cellular proliferate advantage and evaded MEKK1-and TRAIL-mediated apoptosis (Fu et al., 2002a (Fu et al., , b, 2003 . Our findings demonstrate that the effect of bombesin in a low androgen environment is mediated not only through phosphorylation and sumoylation (Gioeli et al., 2002; Fu et al., 2002a) , but also through acetylation of AR. These studies also suggested that transactivation of AR pathway by neuropeptides is subject to multifactorial regulation.
Materials and methods

Constructs and reagents
The pProbasin(ARR) 3 luc was provided by Dr R Matusik (Vanderbilt University, Nashville, TN, USA) (Kasper et al., 1999) . The pPSA5.8luc reporter, the AR-FLAG (provided by Dr MJ Weber, University of Virginia, VA, USA) and, pCMVp300 expression vector (provided by Dr Antonio Giordano, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, PA, USA) were previously described (Fu et al., 2004a; Bouras et al., 2005) . CBP expression vector was provided by Dr L Freedman (Memorial Sloan Kettering Cancer Center, NY, USA). An AR acetylation site mutant (ARK630A) was constructed as described previously (Fu et al., 2000) . The antibodies include the following: anti-AR (441, Santa Cruz, CA, USA), anti-AR (PG-21, Upstate, NY, USA), anti-p300 (05-267, Upstate, NY, USA), anti-p300 (N15, Santa Cruz, CA, USA), anti-PSA (ER-PR8, Dakocytomation, Denmark), anti-b-actin (Chemicon) and anti-Acetylated lysine (9441S, New England Biolabs, MA, USA). The chemicals used were: DHT and bombesin (Sigma Chemical, MO, USA); recombinant NEP (Arris Pharmaceutical, Inc., CA, USA); bombesin/GRP antagonist H3028 and H3038 (kindly provided by Dr Andrew V Schally, Tulane University School of Medicine, LA, USA); CGS24592, a competitive inhibitor of NEP (Novartis Pharmaceutical, NJ, USA); Src kinase inhibitor, PP2; PKCd inhibitor, rotterin; PKC activator, PMA (Calbiochem, La Jolla, CA, USA). siRNA used were: p300 siRNA and siStable nontargeting siRNA (Dharmacon, Lafayette, CO, USA) (negative control), c-Src (sc-29288) and PKCd siRNA (sc-36253, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Cell culture PC-3 and C4-2 cells (a kind gift from Dr WD Heston, Cleveland Clinic, OH, USA) were maintained in RPMI1640 supplemented with 2 mM glutamine, 1% nonessential amino acids, 100 U/ml streptomycin and penicillin, and 10% FCS. The medium was replaced with RPMI 1640 containing 5% CS serum before various treatments. For NEP experiments, C4-2 and LNCaP cells containing NEP were pre-incubated with 10 nM CGS24592 for 2 h and followed with various treatments.
Immunoprecipitation HAT assays IP HAT assays were performed using anti-p300 antibody following the manufacturer's protocol (Upstate, NY, USA) as previously described (Fu et al., 2000 Wang et al., 2004) . Briefly, after various treatments PC cells were collected, pelleted and resuspended in RIPA lysis buffer. Protein concentrations were determined using the Bio-Rad assay. For IP, 500 mg lysate proteins were precipitated with anti-p300 antibody (N15, UPSTATE Inc.) and incubated at 41C overnight. Protein G Sepharose beads (30 ml) were added and incubated at 41C for 1 h. HAT assay cocktail (50 ml) containing 10 ml biotinylated histone H4 peptide was added to the immunoprecipitated p300. The mixture was incubated at 301C for 1 h in a shaking incubator. [ 3 H]acetyl incorporation into the substrates was determined by counting in a liquid scintillation counter (Beckman LS 6000IC). Statistical analysis of HAT activities was performed with paired t-test using SigmaPlot2000 (version 6.00) software (SPSS Inc.) to calculate P-values.
Western blotting and IP Western analysis
Western blotting and IP were performed as described (Sumitomo et al., 2001) . Cells were lysed in RIPA buffer [10 mM Tris-HCl (pH7.4), 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1% sodium deoxycholate, 0.1% SDS, 1.2% aprotinin, 5 mM leupeptin, 4 mM antipain, 1 mM phenylmethylsulfonyl fluoride and 0.1 mM Na 3 VO 4 ]. Proteins, 20 or 50 mg, for each sample were suspended in 2 Â laemmli sample buffer, resolved by SDS-PAGE, and transferred onto nitrocellulose.
For IP, pre-cleared cell lysates (500 mg) were incubated with 1 mg of anti-AR (PG-21, Upstate, NY, USA) antibody overnight followed by 1 h incubation with 40 ml of protein G-Sepharose beads (Amersham Pharmacia Biotech., NJ, USA) at 41C. Immunoprecipitates were collected, washed with radioimmunoprecipitation assay buffer and re-suspended in 2 Â laemmli sample buffer. Western analysis was performed as described above.
Transfection, application of siRNAs and measurements of luciferase activities Transfections using Lipofectamine (Invitrogen Corporation) method were performed following the manufacturer's instructions with minor modifications (Shen et al., 2000) . Plated cells were transfected in six-well plates with a mixture of 10 ml of lipofectamine and 3-4 mg DNA in 1 ml serum-and antibioticsfree RPMI 1640 medium. At 5 h later, RPMI 1640 containing 10% CS and antibiotics was added. After 24 h, cells were trypsinized, and equal numbers of cells plated and cultured for additional 24 h. Cells grown in phenol-free medium containing 5% CS were treated with various reagents. Then cells were lysed for luciferase assays using a luciferase enzyme assay system (Promega Corp., WI, USA). Each transfection experiment was performed in duplicate or triplicate on at least three separate occasions. Results represent an average of three independent experiments with data presented as relative luciferase activity using means of untreated controls as standards. Statistical analysis of luciferase activities was performed with paired t-test.
For the siRNA transfection or cotransfection, PC cells were plated on six-well plates in RPMI 1640 containing 5% CS. After 24 h, cells were transfected with 10 ml of 0.02 mM p300 siRNA (5 0 -AAC CCC UCC UCU UCA GCA CCA-3 0 ; Dharmacon Research, Inc., CO, USA), PKCd, c-Scr siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or siStable nontargeting siRNA (Dharmacon, Lafayette, CO, USA) (negative control) with other DNAs using 10 ml lipofectamine (Invitrogen, CA, USA) per well according to the manufacturer's instructions.
